| Name | 1-(3,4-Difluorophenyl)-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)ure |
|---|---|
| Synonyms |
Urea, N-(3,4-difluorophenyl)-N'-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-
1-(3,4-Difluorophenyl)-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)urea |
| Description | ML 297 (VU 0456810) is a potent and selective GIRK1/2 activator, with an EC50 of 0.16 μM. ML 297 is potential for the treatment of epilepsy[1][2]. |
|---|---|
| Related Catalog | |
| Target |
EC50: 0.16 μM (GIRK1/2), 18 μM (GIRK1/4)[1] |
| In Vitro | ML 297 is completely inactive for GIRK2/3[1]. ML297 shows concentration-dependent efficacy in expressing GIRK1/2 cells and with an EC50 of 162 nM[2]. ML297 shows a complete inability to modulate the activity of HEK-293 cells expressing GIRK2 alone and GIRKGIRK2/3[2]. |
| In Vivo | ML297 (60 mg/kg; i.p.) shows a highly significant ability to both prevent convulsions and prevent fatality of the PTZ treatment[2]. Animal Model: 8-10 months old C57/BL6 male mice (approximately 30 g)[2] Dosage: 60 mg/kg Administration: Intraperitoneal injection Result: Most of the animals neither convulsions nor death. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 377.8±42.0 °C at 760 mmHg |
| Molecular Formula | C17H14F2N4O |
| Molecular Weight | 328.316 |
| Flash Point | 182.3±27.9 °C |
| Exact Mass | 328.113556 |
| PSA | 62.44000 |
| LogP | 4.73 |
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
| Index of Refraction | 1.617 |
| Symbol |
GHS09 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H410 |
| Precautionary Statements | P273-P501 |
| RIDADR | UN 3077 9 / PGIII |